Formulary drug reviews: Sofosbuvir

Hospital Pharmacy

Volumn 49, Issue 5, 2014, Pages 466-478

  Cada, Dennis J ^a   Cong, Jasen ^b   Baker, Danial E ^b  

^a Facts and Comparision Wolters Kluwer Health   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ATAZANAVIR; BOCEPREVIR; CARBAMAZEPINE; CYCLOSPORIN; DACLATASVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; GS 0938; LEDIPASVIR; METHADONE; OXCARBAZEPINE; PEGINTERFERON ALPHA; PHENOBARBITAL; PHENYTOIN; RALTEGRAVIR; RIBAVIRIN; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; RILPIVIRINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; TELAPREVIR; UNCLASSIFIED DRUG;

ANEMIA; BOOK; COUGHING; DIARRHEA; DRUG ANTAGONISM; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; DRUG UTILIZATION; FATIGUE; FEVER; HEADACHE; HEPATITIS C; HUMAN; HYPERICUM PERFORATUM; INSOMNIA; MYALGIA; NAUSEA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; VIRUS TYPING;

EID: 84900490861     PISSN: 00185787     EISSN: 19451253     Source Type: Journal    
DOI: 10.1310/hpj4905-466     Document Type: Review

References (35)

1. Sovaldi [package insert]. Foster City CA: Gilead Sciences; December 2013.
2. Sofosbuvir. ClinicalTrials.gov Web site. http://www.clinicaltrials. gov. Published May 2013. Accessed May 17 2013.
3. Fontana RJ Hughes EA Bifano M et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C [published online ahead of print April 17 2013]. Am J Transplant.
4. Lawitz E Poordad FF Pang PS et al. Sofosbuvir and ledipasvir fi xed-dose combination with and wi thout ribavirin in 1 hepatitis C virus infection (LONESTAR): An open-label randomised phase 2 trial. Lancet. 2014;383(9916):515- 523.
5. Gane EJ Stedman CA Hylan d RH et al. Effi cacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology. 2014;146(3):736-743.e1.
6. Lawitz E Ghalib R Rodriguez-Torres M et al. SVR4 results of a once daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin (RBV) in HCV GT 1 null responders [abstract]. Gas troenterology. 2013;144(5):S374-S375.
7. Lawitz EJ Rodriguez-Torres M Denning J et al. All-oral therapy with nucleotide inhibitors sofosbuvir and GS-0938 for 14 days in treatment-naive genotype 1 hepatitis C (NUCLEAR). J Viral Hepat. 2013;20(10):699-707.
8. Sulkowski MS Gardiner DF Rodriguez-Torres M et al. Sustained virologic response with daclatasvir plus sofosbuvir ± ribavirin (RBV ) in chronic HCV genotype (GT) 1-infected patients who previously failed telaprevir (TVR) or boceprevir (BOC) [abstract]. J Gastroenterol Hepatol. 2013;28(Suppl 2):155.
9. Holmberg SD Spradling PR Moor man AC Denniston MM. Hepatitis C in the United States. N Engl J Med. 2013;368(20):1859-1861.
10. Liang TJ Ghany MG. Current and future therapies for hepatitis C virus infection. N Engl J Med. 2013;368(20):1907-1917.
11. Drenth JP. HCV treatment-no more room for interferonologists N Engl J Med. 2013;368(20):1931-1932.
12. Shiffman ML Benhamou Y Patients with HCV and F1 and F2 fi brosis stage: Treat now or wait Liver Int 2013 33(Suppl 1 105-110.
13. Poordad F Lawitz E Kowdley KV et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med. 2013;368(1):45-53.
14. Ferenci P. Treatment of chronic hepatitis C-are interferons really necessary Liver Int. 2012;32(Suppl 1):108-112.
15. Asselah T Marcellin P. Interferon free therapy with direct acting antivirals for HCV. Liver Int. 2013;33(Suppl 1):93-104.
16. Olysio [pack age insert]. Titusville NJ: Janssen Therapeutics; November 2013.
17. Victrelis [package insert]. Whitehouse Station NJ: Merck & Co Inc; September 2013.
18. Incivek [package insert]. Cambridge MA: Vertex Pharmaceuticals Inc; October 2013.
19. Rodriguez-Torres M Lawitz E Kowdley KV et al. Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatmentnaï ve patients with HCV genotype 1: A randomized 28-day dose-ranging trial. J Hepatol. 2013;58(4):663-668
20. Manns MP Camberg M. Sofosbuvir: The fi nal nail in the coffi n for hepatitis C Lancet Infect Dis. 2013;13(5):378-379.
21. Hebner C Lee YJ Han B et al. In vitro pan-genotypic and combination activity of sofosbuvir (SG-7977) in stable replican cell lines [abstract]. Hepatology. 2012;56(4 Suppl):1066A.
22. Han B Ma H Wong KA. In vitro analyses of HCV NS5B S282T mutants in multiple HCV genotypes show low levels of reduced susceptibility to sofosbuvir (GS-7977) no cross resistance to other cl asses of direct-acting antivirals and hypersensitivity to ribavirin [abstract]. Hepatology. 2012;56(4 Suppl):711A.
23. Svarovskaia ES Dvory-Sobol H Gunicharova V et al. Comprehensive resistance testin g in patients who relapsed after treatment with sofosbuvir (GS-7977)-containing regimens in phase 2 studies [abstract]. Hepatology. 2012;56(4 Suppl):551A.
24. Ghany MG Nelson DR Strader DB Thomas DL Seeff LB; American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Disease. Hepatology. 2011;54(4): 1433-1444.
25. Yee HS Chang MF Pocha C et al; Department of Veterans Affairs Hepatitis C Resource Center Program; National Hepatitis C Program Offi ce. Update on the management and treatment of hepatitis C virus infection: Recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Offi ce. Am J Gastroenterol. 2012;107(5):669-689.
26. Kowdley KV Lawitz E Crespo I et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naï ve patients with hepatitis C genotype-1 infection (ATOMIC): An open-label randomized multicentre phase 2 trial [published online March 14 2013]. Lancet.
27. Gane EJ Stedman GA Hyland RH et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34-44.
28. Lawitz E Mangia A Wyles D et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878-1887.
29. Jacobson IM G ordon SC Kowdley KV et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368(20):1867-1877.
30. German P Mathias A Pang PS et al. Lack of a clinically signifi cant pharmacokinetic drug interaction between sofosbuvir (GS-7977) and GS-5885 or GS-9669 in healthy volunteers [abstract]. Hepatology. 2012;56(4 Suppl):1072A.
31. Mathi as A Cornpropst M Clemons D Denning J Symonds WT. No clinically signifi cant pharmacokinetic drugdrug interactions between sofosbuvir (GS-7977) and the immunosuppressants cyclosporine A or tacrolimus in healthy volunteers [abstra ct]. Hepatology. 2012;56(4 Suppl):1063A.
32. Kirby B Mathias A Rossi S et al. No clinically signifi cant pharmacokinetic drug interactions between sofosbuvir (GS-7977) and HIV antiretrovirals Atri pla rilpivirine darunavir/ritonavir or raltegravir in healthy volunteers [abstract]. Hepatology. 2012;56(4 Suppl):1067A.
33. Gilead submits New Drug Application to U.S. FDA for sofosbuvir for the treatment of hepatitis C [press release] http://www.gilead.com/news/press- releases/2013/4/gileadsubmits-new-drug-application-to-us-fda-for-sofosbuvir- forthe-trea tment-of-hepatitis-c. Accessed May 17 2013.
34. Cox EM. NDA approval letter: Sovaldi (sofosbuvir NDA 204671). US Food and Drug Administration Web site. http://www.accessdata.fda.gov/drugsatfda-docs/ applett er/2013/204 671Orig1s000ltr.pdf. Published December 6 2013. Accessed December 13 2013.
35. Sofosbuvir. ClinicalTrials.gov Web site. http://www.clinicaltrials. gov/ct2/show/record/NCT01896193. Published July 2013. Accessed December 13 2013.